Shopping Cart 0
Cart Subtotal
USD 0

Cellular Biomedicine Group Inc (CBMG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Cellular Biomedicine Group Inc (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm's products comprise clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases. It offers treatment protocol services such as orthopaedic diseases including osteoarthritis and tissue damage; and other indications. CBMG utilizes proprietary cell based technologies to produce raw material, manufacture cells, and conduct cell banking and distribution. The firm has operations in Hong Kong, China and the US. CBMG is headquartered in Cupertino, California, the US.

Cellular Biomedicine Group Inc (CBMG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13

Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15

Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16

Venture Financing 17

Cellular Biomedicine Raises USD 7 Million In Venture Financing 17

Private Equity 18

Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18

Partnerships 19

Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19

Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20

Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21

Merger 22

EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22

Licensing Agreements 23

Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23

Novartis Enters into Licensing Agreement with Cellular Biomedicine 24

Cellular Biomedicine Enters into Option Agreement with Augusta University 26

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27

Equity Offering 28

Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28

Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29

Cellular Biomedicine to Raise Funds through Public Offering of Shares 30

Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31

Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32

Acquisition 33

Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33

Cellular Biomedicine Group Inc-Key Competitors 34

Cellular Biomedicine Group Inc-Key Employees 35

Cellular Biomedicine Group Inc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Joint Venture 37

Recent Developments 38

Strategy And Business Planning 38

Jun 22, 2018: Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland 38

Nov 07, 2017: Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory 39

Sep 22, 2017: Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility 40

Mar 30, 2017: Cellular Biomedicine Group Announces Completion of Wuxi GMP Facility Expansion 41

Jan 03, 2017: Expansion of Cell Production to Produce CAR-T Therapies 42

Financial Announcements 43

Aug 08, 2018: Cellular Biomedicine Group announce second quarter and first half 2018 financial results and business highlights 43

May 08, 2018: Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress 44

Mar 06, 2018: Cellular Biomedicine Group Reports Full Year 2017 Financial Results 45

Nov 09, 2017: Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Operational Highlights 47

Aug 08, 2017: Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights 49

May 08, 2017: Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights 50

Mar 13, 2017: Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress 51

Corporate Communications 53

Jun 20, 2017: Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board 53

Product News 54

05/19/2017: Cellular Biomedicine Group Announces Publication Titled Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody in Conjunction with 2017 ASCO Annual Meeting 54

Clinical Trials 55

Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 55

Other Significant Developments 56

Apr 30, 2018: Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders 56

Jan 18, 2018: CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare's New Start-to-Finish Solution 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellular Biomedicine Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13

Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15

Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16

Cellular Biomedicine Raises USD 7 Million In Venture Financing 17

Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18

Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19

Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20

Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21

EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22

Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23

Novartis Enters into Licensing Agreement with Cellular Biomedicine 24

Cellular Biomedicine Enters into Option Agreement with Augusta University 26

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27

Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28

Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29

Cellular Biomedicine to Raise Funds through Public Offering of Shares 30

Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31

Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32

Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33

Cellular Biomedicine Group Inc, Key Competitors 34

Cellular Biomedicine Group Inc, Key Employees 35

Cellular Biomedicine Group Inc, Other Locations 36

Cellular Biomedicine Group Inc, Subsidiaries 36

Cellular Biomedicine Group Inc, Joint Venture 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Cellular Biomedicine Group Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.